National Day Special | Zhongsheng Medical: The Pinnacle of China’s IVD Industry, with a Bright Future Ahead
Release Time:
2026-10-02 08:18
Source:
In the golden autumn of October, the mountains and rivers are adorned with splendor. During this national holiday celebrated across the country, BIOSINO Biotechnology Co., Ltd. (stock code: 08247.HK) invites you to explore its most innovative and dynamic subsidiary—BIOSINO Medical. From Suzhou to Hefei, from laboratories of the Chinese Academy of Sciences to hospital departments in all 31 provinces, municipalities, and autonomous regions nationwide, this young company is writing a new chapter in China’s in vitro diagnostics industry with “hardcore technology.”
Zhongsheng Medical is committed to the mission of “empowering life through science and technology” and the vision of “striving to become a leading provider of cutting-edge flow cytometry system solutions,” with the goal of establishing itself as a nationally recognized IVD brand with global influence. Zhongsheng Medical’s portfolio includes… China National Biotech (Suzhou) Medical Technology Co., Ltd. and China National Biotech Medical Technology (Hefei) Co., Ltd. Two core operating entities.
Zhongsheng Medical (Suzhou), established in 2009, is located in the Suzhou High-Tech Development Zone—Jiangsu Province Medical Device Industrial Park. It is a high-tech enterprise integrating R&D, manufacturing, sales, and service of in vitro diagnostic (IVD) instruments and associated reagents, and has been awarded numerous honors, including “Demonstration Medical Device Enterprise” by the Ministry of Science and Technology and “High-Tech Enterprise” by Jiangsu Province.
Zhongsheng Medical Technology (Hefei) Co., Ltd. was established in April 2022 as a wholly owned subsidiary of Zhongsheng (Suzhou) Medical Technology Co., Ltd. Located in the Intelligent Science and Technology Park of the Economic Development Zone in Hefei, Anhui Province, the company has completed construction of a production facility spanning nearly 3,000 square meters for flow cytometry instruments and associated reagents. Leveraging the research platforms of the Chinese Academy of Sciences and the Institute of Big Health, the company has assembled an R&D team led by doctoral and master’s degree holders. It has obtained more than 60 patents for flow‑cytometry products and secured over 110 registration certificates for its instruments and reagents. Furthermore, the company was selected through the global screening process of the Institute of Big Health at the Hefei Comprehensive National Science Center and has become a participating shareholder in this initiative.
At the heart of Zhongsheng Medical lies a deep integration of scientific research DNA and industrial capabilities.
Flow cytometers are often referred to as the “CT scanner” of the laboratory and an essential tool in the clinical laboratory, offering advantages such as high sensitivity, high throughput, high precision, and multi-parameter analysis. With the rapid advancement of biotechnology, the applications and market demand for flow cytometry have steadily expanded, with widespread use in immunology, cancer diagnosis and therapy, microbiology, hematology, genetics, and other fields.
With more than a decade of deep expertise in the flow cytometry field, Zhongsheng Medical has developed a fully localized, end-to-end product portfolio that spans from basic clinical applications to advanced, complex assays. The company offers an integrated “instrument–reagent–service” solution, addressing diverse needs across clinical diagnostics, immune monitoring, hematological disease‑assisted diagnosis, and life sciences research.
(1) Flow Cytometer: A Pioneer in the Development of High-End Domestic Instruments
2018
Base model ZS‑AE7S (FlowCyte, single-laser 5-color) It has been approved for market launch. Relying on the transfer and commercialization of flow cytometry core‑technology developed in-house by the Suzhou Institute of Biomedical Engineering, Chinese Academy of Sciences, this instrument was brought to industrial scale by Zhongsheng (Suzhou) Medical, making it one of the earliest flow cytometers to receive domestic approval.
2023
BioCyte (3 lights, 15 colors) Flow cytometer Having obtained certification and been launched on the market, it has successively earned accolades such as “Anhui Province’s First Set” and “People’s Choice Champion for Domestically Produced Flow Cytometers.” This flow cytometer represents a major breakthrough for Zhongsheng Medical in the field of cellular analysis, leveraging advanced optical technologies and sophisticated data‑analysis algorithms to efficiently and accurately process multi‑parameter data, thereby delivering clinicians more comprehensive and precise results. In April 2024, the BioCyte series of flow cytometers was further selected for the Hefei Comprehensive National Science Center’s Institute of Big Health’s globally‑sourced project on “R&D and Industrialization of High‑Throughput Flow Cytometers and Associated Reagents,” successfully overcoming key technical challenges in four‑laser multicolor flow cytometry—including optics, fluidics, and signal acquisition—thus earning authoritative recognition for its technological prowess and innovative capabilities.
2024
AutoProSample A960 Fully Automated Flow-Based Sample Preparation System Now officially launched, it forms a fully automated flow cytometry workstation together with BioCyte. In the field of flow cytometry, standardization and automation of sample preparation have long been major challenges for the industry. After countless rounds of validation and iterative optimization, the Zhongsheng AutoPro Sample A960 has effectively addressed the longstanding issues of automated, standardized sample processing, marking a significant leap in both operational efficiency and analytical accuracy for flow cytometry laboratories and ushering in a revolutionary transformation in flow‑based assays.
2025
BioCyteX (4 lasers, 21 colors) high-end flow cytometer Is China’s first domestically produced product to obtain registration approval for a 4‑color flow cytometer. It officially received certification for market launch in August 2025, with product performance reaching the highest domestic standards, marking a pivotal leap for China in the high-end flow cytometry instrument sector—from “catching up” to “running alongside.”
At the market level, mid-range flow cytometry instruments as of December 2025. Total installed capacity exceeds 600 units. , the installed base now covers all 31 provinces, municipalities, and autonomous regions across China, with some units exported overseas.
(II) Companion Reagents: Multiple Class II reagents have been approved.
The accompanying flow cytometry reagent portfolio encompasses more than 120 assay applications. Key products, including flow‑based absolute cell counting tubes, the Alzheimer’s disease (AD) triple/quadruple assay, multi‑cytokine panels (seven‑, twelve‑, and fourteen‑plex), and HLA‑B27, have already obtained Class II medical device registration certificates. Additionally, the Class III medical device registration application for lymphocyte subset analysis has been accepted and is expected to be approved for market launch shortly.
In 2026, the independently developed by Zhongsheng Medical Alzheimer’s Disease (AD) Combined Detection Kit The company has successfully obtained two Class II medical device registration certificates—namely, the triplex assay for Aβ1‑40/Aβ1‑42/p‑Tau‑181 and the quadruplex assay for Aβ1‑40/Aβ1‑42/p‑Tau‑181/α‑synuclein—thereby officially acquiring the capability to conduct standardized, commercial‑grade testing of core Alzheimer’s disease biomarkers.
The diagnosis of Alzheimer’s disease has long relied on traditional methods such as neuropsychological assessments, cerebrospinal fluid testing, and PET-CT scans. However, these approaches are either time‑consuming and labor‑intensive, invasive, or prohibitively expensive, making them impractical for large‑scale screening. Zhongsheng Medical’s blood‑based AD test requires only a peripheral blood sample, enabling… Non-invasive, simple, and low-cost The assay exhibits both high sensitivity and specificity.
Notably, in 2026, the National Healthcare Security Administration expanded the scope of brain health testing from 185 to 195 items, adding 10 specialized tests and prominently listing assays for Alzheimer’s‑related neurobiomarkers. With favorable policy support and breakthroughs in scientific innovation, Zhongsheng Medical’s first-mover advantage in this field is self‑evident.
Zhongsheng Medical is accelerating its global expansion.
2024
Zhongsheng Medical’s BioCyte flow cytometer has obtained CE certification in accordance with the latest European Union In Vitro Diagnostic Medical Device Regulation (IVDR).
2025
BioCyte has obtained registration approval in Indonesia.
2026
BioCyte has obtained a medical device registration certificate in Malaysia.
In addition, overseas registrations in regions such as Russia, the Middle East, and South Asia are gaining momentum, driving domestic flow cytometry solutions into the global market. It also underscores Zhongsheng Medical’s continued commitment to advancing the compliance and internationalization of its medical devices.
The value of BIOSINO extends far beyond its own products and technologies. As a key implementer of BIOSINO’s “innovation chain, industrial chain, and capital chain” three-chain synergy strategy, BIOSINO is deeply integrated into its parent company’s broader health‑industry ecosystem.
The future is full of promise.
From more than 60 flow‑cytometry patents to over 120 registered medical device approvals, and from 600 installed systems to expanding into Southeast Asia—Zhongsheng Medical has leveraged cutting‑edge technology to address a pivotal question: Can domestically produced IVD solutions achieve independent control in the high‑end market?
The answer is beginning to emerge. BIOSINO has set a clear goal for 2026: to focus on marketing and accelerate its expansion in both domestic and international markets. As the group’s innovation engine, BIOSINO Medical holds a dual strategic position—leading the untapped market for AD diagnostics while riding the wave of domestic substitution in flow cytometry—and its growth potential is rapidly unfolding.
More exciting content
✦
Zhongsheng Medical
✦
Zhongsheng (Suzhou) Medical Technology Co., Ltd. (hereinafter referred to as Zhongsheng Medical (Suzhou)) was established in 2009 and is located in the Suzhou High-Tech Development Zone, within the Jiangsu Province Medical Device Industrial Park. Zhongsheng Medical (Suzhou) is a high-tech enterprise integrating R&D, manufacturing, sales, and service in the field of in vitro diagnostics (IVD) instruments and their associated reagents. To date, the company has been awarded numerous honors, including “Demonstration Medical Device Enterprise” by the Ministry of Science and Technology and “High-Tech Enterprise” by Jiangsu Province. Notably, its ZS‑AE7S flow cytometer was recognized as a Major Scientific and Technological Achievement Transformation Project in Suzhou, Jiangsu Province, in 2018, and in 2019 it received the Gold Award for Outstanding Innovative In Vitro Diagnostic Product at the “Innovation Star” competition. Guided by the mission “Let Technology Care for Life” and the vision “Strive to Become a World-Class Provider of Professional Flow Cytometry Solutions,” the company is committed to building a nationally renowned IVD brand with global influence.
Zhongsheng Medical Technology (Hefei) Co., Ltd. was established in April 2022 as a wholly owned subsidiary of Zhongsheng Medical (Suzhou). Its production facility is located in Phase II of the Intelligent Science and Technology Park in the Economic Development Zone of Hefei, Anhui Province, where nearly 3,000 square meters of space has been dedicated to the manufacturing of flow cytometry instruments and associated reagents. The company’s R&D center is situated at the Institute of Big Health within the Comprehensive National Science Center in Hefei, Anhui. It has assembled an experienced R&D team led by PhDs and master’s degree holders. Zhongsheng is a high-tech enterprise integrating the research, development, manufacturing, sales, and service of cutting-edge scientific instruments, clinical in vitro diagnostic devices, and reagents. As of June 2025, Zhongsheng’s flow cytometry systems have been installed across all 31 provinces, municipalities, and autonomous regions in China, with a portion also exported to international markets.
Other Content